These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34253930)

  • 41. The COVID vaccine pioneer behind southeast Asia's first mRNA shot.
    Mallapaty S
    Nature; 2021 Jun; 594(7862):163. PubMed ID: 34040244
    [No Abstract]   [Full Text] [Related]  

  • 42. Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients.
    Liebers N; Speer C; Benning L; Bruch PM; Kraemer I; Meissner J; Schnitzler P; Kräusslich HG; Dreger P; Mueller-Tidow C; Poschke I; Dietrich S
    Blood; 2022 Jan; 139(1):142-147. PubMed ID: 34669919
    [No Abstract]   [Full Text] [Related]  

  • 43. COVID-19 Vaccines in Patients With Cancer-A Welcome Addition, but There Is Need for Optimization.
    Korompoki E; Gavriatopoulou M; Kontoyiannis DP
    JAMA Oncol; 2021 Aug; 7(8):1113-1114. PubMed ID: 33983372
    [No Abstract]   [Full Text] [Related]  

  • 44. Most Fully Vaccinated Patients With Cancer Have SARS-CoV-2 Antibodies.
    Slomski A
    JAMA; 2021 Sep; 326(9):800. PubMed ID: 34547092
    [No Abstract]   [Full Text] [Related]  

  • 45. mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.
    Molica S; Giannarelli D; Montserrat E
    Eur J Haematol; 2022 Mar; 108(3):264-267. PubMed ID: 34856031
    [No Abstract]   [Full Text] [Related]  

  • 46. SARS-COV-2 vaccination after stem cell transplantation for scleroderma.
    Rimar D; Slobodin G; Paz A; Henig I; Zuckerman T
    Ann Rheum Dis; 2021 Oct; 80(10):1354-1355. PubMed ID: 34049853
    [No Abstract]   [Full Text] [Related]  

  • 47. A global survey of potential acceptance of a COVID-19 vaccine.
    Lazarus JV; Ratzan SC; Palayew A; Gostin LO; Larson HJ; Rabin K; Kimball S; El-Mohandes A
    Nat Med; 2021 Feb; 27(2):225-228. PubMed ID: 33082575
    [TBL] [Abstract][Full Text] [Related]  

  • 48. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.
    Roeker LE; Knorr DA; Thompson MC; Nivar M; Lebowitz S; Peters N; Deonarine I; Momotaj S; Sharan S; Chanlatte V; Hampton B; Butala L; Amato L; Richford A; Lunkenheimer J; Battiato K; Laudati C; Mato AR
    Leukemia; 2021 Sep; 35(9):2703-2705. PubMed ID: 33986431
    [No Abstract]   [Full Text] [Related]  

  • 49. Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
    Parker EPK; Desai S; Marti M; Nohynek H; Kaslow DC; Kochhar S; O'Brien KL; Hombach J; Wilder-Smith A
    Lancet Glob Health; 2022 Mar; 10(3):e326-e328. PubMed ID: 35180408
    [No Abstract]   [Full Text] [Related]  

  • 50. Vaccine-Induced SARS-CoV-2 Antibodies in Inflammatory Diseases.
    Abbasi J
    JAMA; 2021 Oct; 326(14):1365. PubMed ID: 34636872
    [No Abstract]   [Full Text] [Related]  

  • 51. Attitudes and Factors Associated With COVID-19 Vaccine Hesitancy Among Patients With Breast Cancer.
    Villarreal-Garza C; Vaca-Cartagena BF; Becerril-Gaitan A; Ferrigno AS; Mesa-Chavez F; Platas A; Platas A
    JAMA Oncol; 2021 Aug; 7(8):1242-1244. PubMed ID: 34110371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience.
    Cattaneo D; Bucelli C; Cavallaro F; Consonni D; Iurlo A
    Blood Cancer J; 2021 Nov; 11(11):185. PubMed ID: 34824194
    [No Abstract]   [Full Text] [Related]  

  • 53. Safety of COVID-19 Vaccination in Immune-Deficient Patients Receiving Supplemental Immunoglobulin Therapies.
    Squire JD; Joshi AY
    J Clin Immunol; 2021 Oct; 41(7):1527-1530. PubMed ID: 34291391
    [No Abstract]   [Full Text] [Related]  

  • 54. Monoclonal Antibodies for COVID-19 Preexposure Prophylaxis Can't Come Fast Enough for Some People.
    Rubin R
    JAMA; 2021 Nov; 326(19):1895-1897. PubMed ID: 34705039
    [No Abstract]   [Full Text] [Related]  

  • 55. Interim effectiveness of the updated 2023-2024 COVID-19 vaccines in adults with immunocompromizing conditions.
    Pereira MR
    Am J Transplant; 2024 Jun; 24(6):890-891. PubMed ID: 38677653
    [No Abstract]   [Full Text] [Related]  

  • 56. Questions Remain About Who Will Get Monoclonal Antibodies for COVID-19 Preexposure Prophylaxis.
    Rubin R
    JAMA; 2022 Jan; 327(3):207-208. PubMed ID: 34964833
    [No Abstract]   [Full Text] [Related]  

  • 57. When It Comes to SARS-CoV-2 Clearance, People Who Are Immunocompromised Are Not All Alike.
    Rubin R
    JAMA; 2024 Mar; 331(9):723-724. PubMed ID: 38353960
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Divergent Immune Responses to SARS-CoV-2 Vaccines in Immunocompromised Patients.
    Jordan SC; Shin BH; Gadsden TM; Chu M; Petrosyan A; Vo A; Ammerman N; Sethi S; Najjar R; Huang E; Peng A; Toyoda M; Kumar S; Zhang R
    Transplantation; 2022 Jan; 106(1):e90-e91. PubMed ID: 34582140
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Should we be clinically assessing antibody responses to covid vaccines in immunocompromised people?
    Willicombe M; Scanlon M; Loud F; Lightstone L
    BMJ; 2022 Apr; 377():o966. PubMed ID: 35414604
    [No Abstract]   [Full Text] [Related]  

  • 60. Acute Esophageal Necrosis in a Patient With COVID-19.
    Deliwala SS; Gurvits GE
    Am J Gastroenterol; 2021 Oct; 116(10):1977. PubMed ID: 33661144
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.